-
Something wrong with this record ?
Long-term quality assurance of [(18)F]-fluorodeoxyglucose (FDG) manufacturing
L. Gaspar, M. Reich, Z. Kassai, F. Macasek, L. Rodrigo, P. Kruzliak, P. Kovac,
Language English Country United States
Document type Journal Article
NLK
Free Medical Journals
from 2011
PubMed Central
from 2011
Europe PubMed Central
from 2011
PubMed
27508102
Knihovny.cz E-resources
- Publication type
- Journal Article MeSH
Nine years of experience with 2286 commercial synthesis allowed us to deliver comprehensive information on the quality of (18)F-FDG production. Semi-automated FDG production line using Cyclone 18/9 machine (IBA Belgium), TRACERLab MXFDG synthesiser (GE Health, USA) using alkalic hydrolysis, grade "A" isolator with dispensing robotic unit (Tema Sinergie, Italy), and automatic control system under GAMP5 (minus2, Slovakia) was assessed by TQM tools as highly reliable aseptic production line, fully compliant with Good Manufacturing Practice and just-in-time delivery of FDG radiopharmaceutical. Fluoride-18 is received in steady yield and of very high radioactive purity. Synthesis yields exhibited high variance connected probably with quality of disposable cassettes and chemicals sets. Most performance non-conformities within the manufacturing cycle occur at mechanical nodes of dispensing unit. The long-term monitoring of 2286 commercial synthesis indicated high reliability of automatic synthesizers. Shewhart chart and ANOVA analysis showed that minor non-compliances occurred were mostly caused by the declinations of less experienced staff from standard operation procedures, and also by quality of automatic cassettes. Only 15 syntheses were found unfinished and in 4 cases the product was out-of-specification of European Pharmacopoeia. Most vulnerable step of manufacturing was dispensing and filling in grade "A" isolator. Its cleanliness and sterility was fully controlled under the investigated period by applying hydrogen peroxide vapours (VHP). Our experience with quality assurance in the production of [(18)F]-fluorodeoxyglucose (FDG) at production facility of BIONT based on TRACERlab MXFDG production module can be used for bench-marking of the emerging manufacturing and automated manufacturing systems.
BIONT a s Bratislava Slovak Republic
University of Oviedo Central University Hospital of Asturias Oviedo Spain
- 000
- 00000naa a2200000 a 4500
- 001
- bmc16027448
- 003
- CZ-PrNML
- 005
- 20210121144632.0
- 007
- ta
- 008
- 161005s2016 xxu f 000 0|eng||
- 009
- AR
- 035 __
- $a (PubMed)27508102
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Gaspar, Ludovit $u BIONT, a.s.Bratislava, Slovak Republic; 2nd Department of Internal Medicine, Faculty of Medicine, Comenius University and University HospitalBratislava, Slovak Republic.
- 245 10
- $a Long-term quality assurance of [(18)F]-fluorodeoxyglucose (FDG) manufacturing / $c L. Gaspar, M. Reich, Z. Kassai, F. Macasek, L. Rodrigo, P. Kruzliak, P. Kovac,
- 520 9_
- $a Nine years of experience with 2286 commercial synthesis allowed us to deliver comprehensive information on the quality of (18)F-FDG production. Semi-automated FDG production line using Cyclone 18/9 machine (IBA Belgium), TRACERLab MXFDG synthesiser (GE Health, USA) using alkalic hydrolysis, grade "A" isolator with dispensing robotic unit (Tema Sinergie, Italy), and automatic control system under GAMP5 (minus2, Slovakia) was assessed by TQM tools as highly reliable aseptic production line, fully compliant with Good Manufacturing Practice and just-in-time delivery of FDG radiopharmaceutical. Fluoride-18 is received in steady yield and of very high radioactive purity. Synthesis yields exhibited high variance connected probably with quality of disposable cassettes and chemicals sets. Most performance non-conformities within the manufacturing cycle occur at mechanical nodes of dispensing unit. The long-term monitoring of 2286 commercial synthesis indicated high reliability of automatic synthesizers. Shewhart chart and ANOVA analysis showed that minor non-compliances occurred were mostly caused by the declinations of less experienced staff from standard operation procedures, and also by quality of automatic cassettes. Only 15 syntheses were found unfinished and in 4 cases the product was out-of-specification of European Pharmacopoeia. Most vulnerable step of manufacturing was dispensing and filling in grade "A" isolator. Its cleanliness and sterility was fully controlled under the investigated period by applying hydrogen peroxide vapours (VHP). Our experience with quality assurance in the production of [(18)F]-fluorodeoxyglucose (FDG) at production facility of BIONT based on TRACERlab MXFDG production module can be used for bench-marking of the emerging manufacturing and automated manufacturing systems.
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Reich, Michal $u BIONT, a.s. Bratislava, Slovak Republic.
- 700 1_
- $a Kassai, Zoltan $u BIONT, a.s. Bratislava, Slovak Republic.
- 700 1_
- $a Macasek, Fedor $u BIONT, a.s. Bratislava, Slovak Republic.
- 700 1_
- $a Rodrigo, Luis $u University of Oviedo, Central University Hospital of Asturias (HUCA) Oviedo, Spain.
- 700 1_
- $a Kruzliak, Peter $u Department of Chemical Drugs, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences Brno, Czech Republic.
- 700 1_
- $a Kovac, Peter $u BIONT, a.s. Bratislava, Slovak Republic.
- 773 0_
- $w MED00190028 $t American journal of nuclear medicine and molecular imaging $x 2160-8407 $g Roč. 6, č. 3 (2016), s. 154-65
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/27508102 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20161005 $b ABA008
- 991 __
- $a 20210121144630 $b ABA008
- 999 __
- $a ind $b bmc $g 1165762 $s 952078
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2016 $b 6 $c 3 $d 154-65 $e 20160706 $i 2160-8407 $m American journal of nuclear medicine and molecular imaging $n Am J Nucl Med Mol Imaging $x MED00190028
- LZP __
- $a Pubmed-20161005